<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Redox Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Redox Biol</journal-id>
<journal-title-group>
<journal-title>Redox Biology</journal-title>
</journal-title-group>
<issn pub-type="epub">2213-2317</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31606551</article-id>
<article-id pub-id-type="pmc">6812177</article-id>
<article-id pub-id-type="publisher-id">S2213-2317(19)31060-2</article-id>
<article-id pub-id-type="doi">10.1016/j.redox.2019.101334</article-id>
<article-id pub-id-type="publisher-id">101334</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Altered inflammasome machinery as a key player in the perpetuation of Rett syndrome oxinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="au1">
<name>
<surname>Pecorelli</surname>
<given-names>Alessandra</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="fn" rid="fn1">l</xref>
</contrib>
<contrib contrib-type="author" id="au2">
<name>
<surname>Cordone</surname>
<given-names>Valeria</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="fn" rid="fn1">1</xref>
</contrib>
<contrib contrib-type="author" id="au3">
<name>
<surname>Messano</surname>
<given-names>Nicolò</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
</contrib>
<contrib contrib-type="author" id="au4">
<name>
<surname>Zhang</surname>
<given-names>Changqing</given-names>
</name>
<xref ref-type="aff" rid="aff3">c</xref>
</contrib>
<contrib contrib-type="author" id="au5">
<name>
<surname>Falone</surname>
<given-names>Stefano</given-names>
</name>
<xref ref-type="aff" rid="aff4">d</xref>
</contrib>
<contrib contrib-type="author" id="au6">
<name>
<surname>Amicarelli</surname>
<given-names>Fernanda</given-names>
</name>
<xref ref-type="aff" rid="aff4">d</xref>
</contrib>
<contrib contrib-type="author" id="au7">
<name>
<surname>Hayek</surname>
<given-names>Joussef</given-names>
</name>
<xref ref-type="aff" rid="aff5">e</xref>
</contrib>
<contrib contrib-type="author" id="au8">
<name>
<surname>Valacchi</surname>
<given-names>Giuseppe</given-names>
</name>
<email>gvalacc@ncsu.edu</email>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="aff" rid="aff6">f</xref>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>a</label>Plants for Human Health Institute, Dept. of Animal Science, NC Research Campus, NC State University, Kannapolis, 28081, NC, USA</aff>
<aff id="aff2"><label>b</label>Dept. of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44121, Ferrara, Italy</aff>
<aff id="aff3"><label>c</label>Plants for Human Health Institute, Dept. of Plant and Microbial Biology, NC Research Campus, NC State University, Kannapolis, 28081, NC, USA</aff>
<aff id="aff4"><label>d</label>Dept. of Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy</aff>
<aff id="aff5"><label>e</label>Child Neuropsychiatry Unit, University General Hospital, Azienda Ospedaliera Universitaria Senese, 53100, Siena, Italy</aff>
<aff id="aff6"><label>f</label>Dept. of Food and Nutrition, Kyung Hee University, 02447, Seoul, South Korea</aff>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author. Dept. of Animal Science, North Carolina State University, Plants for Human Health Institute, NC Research Center, 28081, Kannapolis, NC, USA. <email>gvalacc@ncsu.edu</email></corresp>
<fn id="fn1">
<label>1</label>
<p id="ntpara0010">Authors contributed equally.</p>
</fn>
</author-notes>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>10</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>28</volume>
<elocation-id>101334</elocation-id>
<history>
<date date-type="received">
<day>4</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 The Authors</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
</license>
</permissions>
<abstract id="abs0010">
<p>Rett syndrome (RTT) is a progressive neurodevelopmental disorder mainly caused by mutations in the X-linked MECP2 gene. RTT patients show multisystem disturbances associated with an oxinflammatory status. Inflammasomes are multi-protein complexes, responsible for host immune responses against pathogen infections and redox-related cellular stress. Assembly of NLRP3/ASC inflammasome triggers pro-caspase-1 activation, thus, resulting in IL-1β and IL-18 maturation. However, an aberrant activation of inflammasome system has been implicated in several human diseases. Our aim was to investigate the possible role of inflammasome in the chronic subclinical inflammatory condition typical of RTT, by analyzing this complex in basal and lipopolysaccharide (LPS)+ATP-stimulated primary fibroblasts, as well as in serum from RTT patients and healthy volunteers. RTT cells showed increased levels of nuclear p65 and ASC proteins, pro-IL-1β mRNA, and NLRP3/ASC interaction in basal condition, without any further response upon the LPS + ATP <italic>stimuli</italic>. Moreover, augmented levels of circulating ASC and IL-18 proteins were found in serum of RTT patients, which are likely able to amplify the inflammatory response. Taken together, our findings suggest that RTT patients exhibited a challenged inflammasome machinery at cellular and systemic level, which may contribute to the subclinical inflammatory state feedback observed in this pathology.</p>
</abstract>
<abstract abstract-type="graphical" id="abs0015">
<title>Graphical abstract</title>
<p>
<fig id="undfig1" position="anchor">
<alt-text id="alttext0010">Image 1</alt-text>
<graphic xlink:href="fx1"></graphic>
</fig>
</p>
</abstract>
<abstract abstract-type="author-highlights" id="abs0020">
<title>Highlights</title>
<p>
<list id="ulist0010" list-type="simple">
<list-item id="u0010">
<label>•</label>
<p id="p0010">RTT cell shows a constitutive NFκB activation.</p>
</list-item>
<list-item id="u0015">
<label>•</label>
<p id="p0015">Aberrant activation of inflammasome system is evident in RTT.</p>
</list-item>
<list-item id="u0020">
<label>•</label>
<p id="p0020">This new evidence can explain the demonstrated subclinical inflammation in RTT.</p>
</list-item>
</list>
</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>NLRP3</kwd>
<kwd>ASC</kwd>
<kwd>Inflammatory status</kwd>
<kwd>Cytokines</kwd>
<kwd>MeCP2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<label>1</label>
<title>Introduction</title>
<p id="p0025">Rett syndrome (RTT; OMIM identifier #312750), first described by the physician Andreas Rett [<xref ref-type="bibr" rid="bib1">1</xref>], is a severe neurodevelopmental disorder, predominantly affecting females (approx. 1 per 10,000 live births) [<xref ref-type="bibr" rid="bib2">2</xref>]. In 90–95% of patients diagnosed with RTT, the disorder is due to <italic>de novo</italic> loss-of-function mutations in the X-linked <italic>MECP2</italic> gene, which encodes methyl-CpG binding protein 2 [<xref ref-type="bibr" rid="bib3">3</xref>].</p>
<p id="p0030">After 6-18-months of apparently normal development [<xref ref-type="bibr" rid="bib4">4</xref>], RTT leads to both developmental regression, involving loss of hand skills, motor skills and speech, and a number of co-morbidities, including breathing disturbances, seizures, gastro-intestinal complications, and scoliosis [<xref ref-type="bibr" rid="bib5">5</xref>], allowing to define RTT as a ‘spectrum disorder’. Today, the complete pathogenic mechanisms linking MECP2 dysfunction to RTT symptoms are still not clear.</p>
<p id="p0035">In the last decade, a growing body of evidence supported the idea that an OxInflammation condition, observed in brain and peripheral compartments of both RTT patients and animal models, could be involved in RTT pathophysiology [<xref ref-type="bibr" rid="bib6">6</xref>]. This condition in RTT is due to the concomitant dysregulation of redox and immune homeostasis and characterized by a subclinical inflammatory status coupled with an increased production of oxidant species and a perturbed defense response [<xref ref-type="bibr" rid="bib6">[6]</xref>, <xref ref-type="bibr" rid="bib7">[7]</xref>, <xref ref-type="bibr" rid="bib8">[8]</xref>, <xref ref-type="bibr" rid="bib9">[9]</xref>]. Based on recent findings, cytosolic molecular complexes termed inflammasomes have emerged as central mediators in the crosstalk between redox imbalance and inflammation associated with a wide range of diseases [<xref ref-type="bibr" rid="bib10">10</xref>]. The assembly of inflammasomes occurs following the recognition of multiple diverse endogenous and exogenous signals such as “pathogen-associated” or “danger-associated molecular patterns” (PAMPs or DAMPs) by a cytosolic subset of “pattern recognition receptors” (PRRs), named “nucleotide-binding domain and leucine-rich repeat-containing (NLR) proteins” [<xref ref-type="bibr" rid="bib11">11</xref>]. The activation of these intracellular sensors such as NLRP3, the most widely studied member among them, triggers the oligomerization and the recruitment of the adaptor protein ASC, which in turn is able to recruit the effector protein pro-caspase 1 [<xref ref-type="bibr" rid="bib12">12</xref>]. The proximity-induced pro-caspase 1 auto-cleavage leads to the generation of the catalytically active caspase 1 (CASP1), which prompts the downstream responses, consisting of the conversion of both pro-IL-1β and pro-IL-18 to their biologically active forms, and/or the proteolytic action of gasdermin D (GSDMD). This latter promotes the release of GSDMD N-terminal fragments that oligomerize into ring-shaped structures in membranes. GSDMD pores allow cells to release passively their cytoplasmic content in a size-dependent manner (<italic>i.e.,</italic> cytokines like IL-1β) [<xref ref-type="bibr" rid="bib13">13</xref>] or drive cells towards pyroptotic death [<xref ref-type="bibr" rid="bib11">11</xref>]. Besides its involvement in innate immune responses, NLRP3 inflammasome has been demonstrated to have a role in a wide range of inflammatory diseases, cancer, metabolic and autoimmune disorders, and aging [<xref ref-type="bibr" rid="bib14">[14]</xref>, <xref ref-type="bibr" rid="bib15">[15]</xref>, <xref ref-type="bibr" rid="bib16">[16]</xref>, <xref ref-type="bibr" rid="bib17">[17]</xref>, <xref ref-type="bibr" rid="bib18">[18]</xref>, <xref ref-type="bibr" rid="bib19">[19]</xref>]. The inflammasome pathway is implicated even in the neuroinflammation observed in neurodegenerative disorders, like multiple sclerosis, Alzheimer's and Parkinson's disease [<xref ref-type="bibr" rid="bib20">20</xref>,<xref ref-type="bibr" rid="bib21">21</xref>] and in neurodevelopmental pathologies, like autistic spectrum disorders (ASDs) [<xref ref-type="bibr" rid="bib22">22</xref>].</p>
<p id="p0040">Since the inflammasome pathway could contribute to the characteristic OxInflammatory status of RTT, this work was aimed at investigating the activation state of the inflammasome in fibroblasts and serum samples from RTT patients. We revealed that a deregulated activation of inflammasome pathway occurs in RTT, as proved by the increased constitutive levels of inflammasome components in patient-derived serum and fibroblast cell lines and by the inability of RTT cells to activate properly this pathway after further pro-inflammatory challenges.</p>
</sec>
<sec id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec2.1">
<label>2.1</label>
<title>Antibodies</title>
<p id="p0045">Cell Signaling Technology, Inc. (Danvers, MA, USA) supplied the following antibodies: anti-nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) p65 subunit antibody (cat. 8242; dil. 1:1,000); anti-NACHT, LRR and PYD domains-containing protein 3 (NLRP3) antibody (cat. 13158; dil. for WB 1:500 and for IF 1:100); anti-caspase 1 (CASP1) antibody (cat. 2225; dil. 1:1,000), anti-cleaved-IL-1β (cat. 83186; dil. 1:100); anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (cat. 5174; dil. 1:5,000); anti-histone deacetylase 1 (HDAC1) antibody (cat. 8242; dil. 1:1,000), and peroxidase-conjugated anti-rabbit secondary antibody (cat. 7074; dil. 1:10,000). Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) provided the anti-apoptosis-associated speck-like protein containing CARD (ASC) (cat. sc-271054; dil. for WB 1:800 and for IF 1:200) antibody. Both AlexaFluorTM 488 goat anti-rabbit IgG (H + L) (cat. A-11008; dil. 1:1,000) and AlexaFluorTM 568 goat anti-mouse IgG (H + L) (cat. A-11004; dil. 1:1,000) antibodies were provided by Thermo Fisher Scientific (Waltham, MA, USA). The peroxidase-conjugated anti-mouse secondary antibody (cat. 170–6515; dil. 1:10,000) was supplied by Bio-Rad Laboratories (Hercules, CA, USA).</p>
</sec>
<sec id="sec2.2">
<label>2.2</label>
<title>Study approval</title>
<p id="p0050">Female patients with classical RTT and healthy sex- and age-matched controls were enrolled for the study. All patients were admitted to the Child Neuropsychiatry Unit of the University Hospital of Siena (Siena, Italy). Diagnosis and inclusion/exclusion criteria of RTT were set in agreement with revised RTT nomenclature consensus [<xref ref-type="bibr" rid="bib4">4</xref>]. The study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki), and the protocol was approved by the Ethics Committee of Institutional Review Board of University Hospital, Azienda Ospedaliera Universitaria Senese (AOUS), Siena, Italy. A written form of the informed consents was signed from either the parents or the legal tutors of the participants.</p>
</sec>
<sec id="sec2.3">
<label>2.3</label>
<title>Human fibroblasts culture</title>
<p id="p0055">Skin biopsies from healthy donors (CTR; N = 6) were taken during health checks or by donations, while skin biopsies from RTT patients (N = 6; age: 20 ± 3.8, expressed as mean ± SD) were obtained during the periodic clinical checks-up. Human skin fibroblasts were isolated by 3-mm skin punch biopsy, as previously described [<xref ref-type="bibr" rid="bib23">23</xref>]. Before the experimental procedure, fibroblasts were stained for Vimentin and checked for mycoplasma contamination. Cells were cultured with DMEM medium, containing 10% (v/v) fetal bovine serum (cat. 10-014-CV and cat. 35-011-CV, respectively, Corning, New York, NY, USA), antibiotics (100 IU/ml penicillin, 100 mg/ml streptomycin) (cat. 30-002-CI; Corning) and incubated in humidified atmosphere (5% CO<sub>2</sub>) at 37 °C. All experiments were performed by using fibroblasts between the third and fifth passage <italic>in vitro</italic>.</p>
</sec>
<sec id="sec2.4">
<label>2.4</label>
<title>Cell treatment with LPS and ATP</title>
<p id="p0060">CTR and RTT fibroblasts were seeded (5,000 cells/cm<sup>2</sup>) in complete medium and after 48 h, cells were starved with 1% FBS-containing medium for 15 h to minimize cell proliferation. Cells were then incubated with or without 100 μg/ml lipopolysaccharide (LPS, dissolved in water), for 6 h in 1% FBS-supplemented medium and with 5 mM adenosine triphosphate (ATP, dissolved in water) for additional 30 min (cat. L2630 and cat. A6419, respectively, Sigma-Aldrich, St. Louis, MO, USA). The LPS concentration was calculated based on the evaluation of <italic>NLRP3</italic> gene expression, in response to different concentrations (0, 10, 50, 100 and 200 μg/ml for 6 h), while the ATP treatment was established based on literature papers [<xref ref-type="bibr" rid="bib24">24</xref>,<xref ref-type="bibr" rid="bib25">25</xref>]. The chosen concentration of LPS (100 μg/ml) induced an inflammasome-related response and no cell death was observed (<xref ref-type="sec" rid="appsec1">Supplementary Fig. S1</xref>).</p>
</sec>
<sec id="sec2.5">
<label>2.5</label>
<title>Western immunoblot analysis</title>
<p id="p0065">Fibroblasts were lysed in RIPA buffer (cat. J62524, Alfa Aesar, Tewksbury, MA, USA), supplemented with 1% (v/v) protease inhibitors and 1% (v/v) phosphatase inhibitors (cat. 78430 and cat. 1862495, respectively, Thermo Fisher Scientific, Waltham, MA, USA). After three freezing-thawing cycles, cell lysates were centrifuged at 17,000×<italic>g</italic> for 15 min at 4 °C, and supernatants were used for the evaluation of total protein concentration, by using the Quick Start™ Bradford Protein Assay Kit (cat. 5000201, Bio-rad Laboratories) and bovine serum albumin (BSA) as standard. Samples were denatured and run in triplicates on 10–15% polyacrylamide gels, as previously reported [<xref ref-type="bibr" rid="bib26">26</xref>]. Proteins were transferred from polyacrylamide gels onto polyvinylidene difluoride (PVDF) membranes by electrophoretic transfer. Non-specific binding sites were blocked at room temperature for 1 h with 5% (w/v) Blotting-Grade Blocker (cat. 170–6404, Bio-Rad Laboratories), in Tris-buffer saline containing 0.1% (v/v) Tween-20 (cat. P5927, Sigma–Aldrich) (TBS-T). Membranes were first incubated overnight with primary antibodies-containing TBS-T (see the antibodies section), and then with anti-rabbit or anti-mouse peroxidase-conjugated secondary antibodies diluted in TBS-T for 2 h at room temperature (see the antibodies section). The protein bands were detected by using Clarity™ Western ECL Substrate Kit (cat. 1705060, Bio-Rad Laboratories) and ChemiDoc™ MP Imaging System hardware and software (Bio-Rad Laboratories). Images of bands were analyzed by the Nonlinear Dynamics TotalLab software (TotalLab Ltd, Newcastle upon Tyne, UK). Data were normalized against HDAC1 or GAPDH, depending on nuclear or cytosolic/total proteins analyzed, and results were given as arbitrary units.</p>
</sec>
<sec id="sec2.6">
<label>2.6</label>
<title>Subcellular protein fractionation</title>
<p id="p0070">Nuclear and cytoplasmic protein fractions were prepared by using the Nuclear Extraction Kit (cat. 2900, Merck Millipore, Burlington, MA, USA). Briefly, cells were washed with PBS and then were lysed with Cytoplasmic Lysis Buffer, containing 0.5 mM dithiothreitol (DTT) and 0.1% (v/v) protease inhibitor cocktail. After homogenization, the disrupted cell suspension was centrifuged at 8,000×<italic>g</italic> for 20 min at 4 °C, and the supernatant, containing the cytosolic portion, was recovered. The remaining pellet was then resuspended in Nuclear Extraction Buffer supplemented with 0.5 mM DTT and 0.1% (v/v) protease inhibitor cocktail and homogenized. The resulting nuclear suspension was centrifuged at 16,000×<italic>g</italic> for 5 min at 4 °C and the supernatant, containing the nuclear extract, was collected [<xref ref-type="bibr" rid="bib27">27</xref>]. Total protein concentration was determined by Bradford analysis (Quick Start™ Bradford Protein Assay Kit, cat. 5000201, Bio-rad Laboratories).</p>
</sec>
<sec id="sec2.7">
<label>2.7</label>
<title>RNA extraction and real time RT-PCR analysis</title>
<p id="p0075">As previously reported [<xref ref-type="bibr" rid="bib28">28</xref>], total RNA was extracted from fibroblasts by using Aurum Total RNA Mini Kit (cat.732–6820, Bio-Rad), removing genomic contamination by using DNase I, as recommended by the supplier. RNA (1 μg) was converted into complementary DNA by using iScript Reverse Transcription kit (cat. 1708841, Bio-Rad). The obtained cDNA (diluted 1:10) was used for the real time PCR step with SsoAdvanced Universal SYBR Green Supermix (cat. 172–5271, Bioline, London, UK) in a LightCycler® 480 Instrument (Roche, Indianapolis, IN, USA). Primers were synthetized by Sigma-Aldrich (St. Louis, MO, USA): <italic>NLRP3</italic> (forward, 5′-CGGGGCCTCTTTTCAGTTCT-3′; reverse, 5′-CCCCAACCACAATCTCCGAA-3′) (Primer BLAST, accession number: <ext-link ext-link-type="uri" id="intref0010" xlink:href="ncbi-n:NM_004895.4">NM_004895.4</ext-link>); <italic>CASP1</italic> (forward, 5′-CCGTTCCATGGGTGAAGGTA-3′; reverse, 5′-TGCCCCTTTCGGAATAACGG-3′) (Primer BLAST, accession number: <ext-link ext-link-type="uri" id="intref0015" xlink:href="ncbi-n:NM_033292.4">NM_033292.4</ext-link>); <italic>IL-1β</italic> (forward, 5′-CACGATGCACCTGTACGATCA-3'; reverse, 5′-GTTGCTCCATATCCTGTCCCT-3′) [<xref ref-type="bibr" rid="bib58">58</xref>]; <italic>GAPDH</italic> (forward, 5′-TGACGCTGGGGCTGGCATTG-3′; reverse, 5′- GGCTGGTGGTCCAGGGGTCT-3′) [<xref ref-type="bibr" rid="bib26">26</xref>].</p>
<p id="p0080">The PCR protocol was set as follows: polymerase activation and initial denaturation at 95 °C for 30 s, and 40 cycles of 95 °C for 15 s and 60 °C for 60 s. In order to check the presence of possible co-amplified undesired targets, melt-curve analysis was performed for all primer pairs (65 °C–95 °C, 0.5 °C increment, 2 s/step). Quantitative relative gene expression was calculated by using the 2<sup>−ΔΔCt</sup> method [<xref ref-type="bibr" rid="bib29">29</xref>], using GAPDH as the reference mRNA and one of the controls as the internal calibrator. Each sample was processed by analyzing three replicates.</p>
</sec>
<sec id="sec2.8">
<label>2.8</label>
<title>Immunofluorescence analysis</title>
<p id="p0085">Fibroblasts were seeded (5,000 cells/cm<sup>2</sup>) and grown on coverslips in complete medium. CTR and RTT cells were starved and treated with LPS + ATP, as described in the “Cell treatment with LPS and ATP” sub-section. As previously reported [<xref ref-type="bibr" rid="bib23">23</xref>], cells were washed twice with <sc>d</sc>-phosphate buffered saline (PBS), then fixed in 10% (w/v) neutral buffered formalin solution for 10 min, and permeabilized in PBS containing 0.25% (v/v) Triton X-100 for 10 min at 4 °C. Non-specific binding sites were blocked with 3% (w/v) BSA in PBS for 30 min. Cells were then incubated with primary antibodies that were diluted in PBS containing 0.5% (w/v) BSA at 4 °C overnight (see the “Antibodies” section for information about dilutions). After three washes with PBS, cells were incubated with AlexaFluor 488 or AlexaFluor 568 antibodies-containing PBS at 4 °C for 1 h (see the “Antibodies” section for information about dilutions). After five washes with PBS, cells were incubated with a solution of 4′,6-diamidino-2-phenylindole (DAPI)-containing PBS for 1 min (dil. 1:20,000) and mounted with ProLong Diamond mounting medium (cat. D1306 and cat. P36965, respectively, Thermo Fisher Scientific). Cells were observed and photographed by confocal microscopy (objective 40×) by using a Zeiss LSM 710 microscope (Carl Zeiss, Thornwood, NY, USA) and Zen 2008 Software (Carl Zeiss Microscopy GmbH, Jena, Germany). Digital images were analyzed by using an open source Java-based Fiji-ImageJ image processing package, and the coloc2 plug-in for colocalization. Results were given as Pearson coefficients [<xref ref-type="bibr" rid="bib30">30</xref>].</p>
</sec>
<sec id="sec2.9">
<label>2.9</label>
<title>Serum sampling</title>
<p id="p0090">Serum samples were obtained from female patients with clinical diagnosis of typical RTT and MECP2 mutation (n = 42; median age: 15) and healthy controls (n = 16; median age: 16). As previously reported [<xref ref-type="bibr" rid="bib31">31</xref>], fasting venous blood was collected at 8–10 a.m. following an overnight fast and all manipulations were carried out within 2 h. Blood was collected in tubes without anticoagulants and allowed to clot at RT. Following centrifugation at 1,500×<italic>g</italic> for 10 min, the sera were transferred into clean tubes. Serum samples were stored at −80 °C for further immunoblot (ASC and CASP1) or ELISA (IL-18) analyses.</p>
</sec>
<sec id="sec2.10">
<label>2.10</label>
<title>ASC oligomerization assay</title>
<p id="p0095">For the ASC oligomerization assay, five μl of serum were suspended in 500 μL PBS and cross-linked with 2 mM disuccinimidyl suberate (DSS) for 30 min a room temperature. Cross-linked samples were centrifuged at 10,000×<italic>g</italic> for 15 min at 4 °C. The pellets containing ASC oligomers were boiled with 2x protein loading buffer for 5 min for Western blot analysis.</p>
</sec>
<sec id="sec2.11">
<label>2.11</label>
<title>Enzyme-linked immunosorbent assay (ELISA)</title>
<p id="p0100">Serum concentrations of IL-18 were determined by ELISA using a commercial kit (RayBiotech Life, Peachtree Corners, GA, USA), according to the manufacturer's instructions. All samples were analyzed in duplicate. A calibration curve was performed using IL-18 as a standard. The optical absorbance was measured with a microplate reader at 450 nm, and results are expressed as pg/mL. The lower limit of detection for IL-18 was 0.5 pg/mL.</p>
</sec>
<sec id="sec2.12">
<label>2.12</label>
<title>Statistics</title>
<p id="p0105">Statistical analyses were performed by using GraphPad Prism 6 and Statsoft Statistica10 softwares. One-way or factorial ANOVA, with <italic>post-hoc</italic> Tukey's tests were applied. The null hypothesis was rejected with P less than 0.05. All data were expressed as means ± standard deviations (SD).</p>
</sec>
</sec>
<sec id="sec3">
<label>3</label>
<title>Results</title>
<sec id="sec3.1">
<label>3.1</label>
<title>Constitutive nuclear translocation of NF-κB p65 and increased levels of cleaved IL-1β in RTT fibroblasts</title>
<p id="p0110">First critical step in inflammasome activation is the transcriptional up-regulation of inflammasome components via nuclear factor (NF)-κB signaling. As shown in <xref ref-type="fig" rid="fig1">Fig. 1</xref>A, RTT fibroblasts revealed highly augmented levels of nuclear NF-κB p65 subunit in basal condition (P &lt; 0.01), as compared to unstimulated CTR. However, while CTR fibroblasts responded to LPS + ATP treatment by increasing p65 nuclear translocation over time (after 2 and 6 h) (P &lt; 0.05), p65 nuclear levels did not increase any further after LPS + ATP in RTT fibroblasts (<xref ref-type="fig" rid="fig1">Fig. 1</xref>A).<fig id="fig1"><label>Fig. 1</label><caption><p>Constitutive nuclear translocation of NF-κB p65 and expression of cleaved IL-1β in RTT fibroblasts.</p><p><bold>Panel A.</bold> Representative Western blots for NF-κB p65 in nuclear extracts from control and RTT fibroblasts stimulated with LPS 100 μg/ml for 2 and 6 h plus ATP 5 mM for 30 min. Quantification is showed in bottom panel. Data are given as means ± SD. <bold>Panel B.</bold> The mRNA levels of pro-IL-1β were analyzed by real-time RT-PCR. Data are expressed as 2<sup>−ΔΔCt</sup>, using GAPDH as the reference, and one of the controls as the internal calibrator. Data are given as means ± SD. <bold>Panel C.</bold> Immunofluorescence for cleaved IL-1β in control and RTT fibroblasts stimulated with LPS 100 μg/ml for 6 h and ATP 5 mM for 30 min. Nuclei are stained with DAPI. Bar = 15 μm. CTR, control; RTT, Rett syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P &lt; 0.05; **P &lt; 0.01. Results were analyzed by factorial ANOVA (with 2 × 2 × 3 design for panel A, and 2 × 2 design for panel B), with post-hoc Tukey's multiple comparisons test.</p></caption><alt-text id="alttext0030">Fig. 1</alt-text><graphic xlink:href="gr1"></graphic></fig></p>
<p id="p0115">NF-κB–activating <italic>stimulus</italic> induces elevated expression of pro-IL-1β, a key pro-inflammatory cytokine involved in the inflammasome pathway [<xref ref-type="bibr" rid="bib32">32</xref>]. RTT fibroblasts displayed a robust constitutive pro-IL-1β mRNA expression in basal condition when compared to unstimulated CTR cells (P &lt; 0.05) (<xref ref-type="fig" rid="fig1">Fig. 1</xref>B). As expected, increased transcriptional levels of pro-IL-1β have been detected in LPS + ATP-stimulated CTR cells (P &lt; 0.05; as compared to untreated CTR); whereas no further changes in pro-IL-1β levels were noticed in RTT fibroblasts after the pro-inflammatory stimulation (<xref ref-type="fig" rid="fig1">Fig. 1</xref>B).</p>
<p id="p0120">In line with these results, immunofluorescence analysis for the cleaved IL-1β revealed an increase of green signal in cytoplasmic compartment of untreated RTT cells as compared to basal CTR fibroblasts (<xref ref-type="fig" rid="fig1">Fig. 1</xref>C). No change in fluorescence intensity was observed in RTT fibroblasts upon LPS + ATP stimulation when compared to the unstimulated condition (<xref ref-type="fig" rid="fig1">Fig. 1</xref>C). On the other hand, an increased green fluorescence for the mature IL-1β was evident in CTR fibroblasts after LPS + ATP treatment (<xref ref-type="fig" rid="fig1">Fig. 1</xref>C).</p>
</sec>
<sec id="sec3.2">
<label>3.2</label>
<title>NLRP3 inflammasome components are constitutively expressed at high levels in RTT fibroblasts</title>
<p id="p0125">In addition to NF-κB p65, other key players in the inflammasome system were analyzed, including NLRP3 and ASC. Basal RTT fibroblasts showed higher NLRP3 protein levels compared to CTR (P &lt; 0.05), without any evident change after pro-inflammatory stimulation (<xref ref-type="fig" rid="fig2">Fig. 2</xref>A). Instead, NLRP3 levels in CTR fibroblasts were increased significantly upon LPS + ATP treatment (P &lt; 0.05; as compared to untreated CTR) (<xref ref-type="fig" rid="fig2">Fig. 2</xref>A).<fig id="fig2"><label>Fig. 2</label><caption><p>Increased levels of NLRP3 and ASC in basal RTT fibroblasts.</p><p><bold>Panel A.</bold> Representative images and densitometric analysis of Western blotting for NLRP3 in control and RTT fibroblasts incubated without or with LPS 100 μg/ml for 6 h plus ATP 5 mM. <bold>Panel B.</bold> Representative images and densitometric analysis of Western blots for ASC in control and RTT fibroblasts stimulated with LPS 100 μg/ml for 2 and 6 h plus ATP 5 mM. Data are given as means ± SD. CTR, control; RTT, Rett syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P &lt; 0.05; **P &lt; 0.01. Results were analyzed by Two-way ANOVA, with post-hoc Tukey's multiple comparisons test.</p></caption><alt-text id="alttext0035">Fig. 2</alt-text><graphic xlink:href="gr2"></graphic></fig></p>
<p id="p0130">Similarly, an increase of ASC levels could be detected in basal RTT fibroblasts as compared to untreated CTR (P &lt; 0.01), but with no statistically significant variation in response to the pro-inflammatory <italic>stimuli</italic> (<xref ref-type="fig" rid="fig2">Fig. 2</xref>B). On the other hand, in CTR cells ASC levels were low in basal conditions, but significantly increased after LPS + ATP stimulation (P &lt; 0.05) (<xref ref-type="fig" rid="fig2">Fig. 2</xref>B).</p>
</sec>
<sec id="sec3.3">
<label>3.3</label>
<title>RTT fibroblasts show an increased colocalization between NLRP3 and ASC</title>
<p id="p0135">To determine if high constitutive levels of the inflammasome components in RTT cells paralleled with inflammasome assembly, we assessed the NLRP3-ASC interaction by evaluating their cellular localization by immunofluorescence (<xref ref-type="fig" rid="fig3">Fig. 3</xref>).<fig id="fig3"><label>Fig. 3</label><caption><p>Increased formation of NLRP3/ASC inflammasome complexes in RTT fibroblasts.</p><p><bold>Panel A.</bold> Confocal images showing localization of NLRP3 (green fluorescence) and ASC (red fluorescence) in control and RTT fibroblasts stimulated with LPS 100 μg/ml for 6 h and ATP 5 mM for 30 min. Overlay of the green and red channel shows that there is colocalization between NLRP3 and ASC. Nuclei are stained with DAPI. Bar = 15 μm. CTR, control; RTT, Rett syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P &lt; 0.05. <bold>Panel B.</bold> Pearson's correlation coefficient values for colocalization of NLRP3 and ASC. Co-localization data were given as means ± SD. Results were analyzed by Two-way ANOVA, with post-hoc Tukey's multiple comparisons test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)</p></caption><alt-text id="alttext0040">Fig. 3</alt-text><graphic xlink:href="gr3"></graphic></fig></p>
<p id="p0140">In CTR cells, the LPS + ATP treatment induced an increase of the NLRP3-related immunofluorescence signal into the cytoplasmic and perinuclear region (likely, endoplasmic reticulum), as well as an enhanced ASC-related signal into the cytosol, as compared to unstimulated CTR cells (<xref ref-type="fig" rid="fig3">Fig. 3</xref>A). Conversely, in RTT fibroblasts, basal signals of both NLRP3 and ASC are higher and localized in the cytosolic compartment, whereas LPS + ATP stimulation did not affect the cytosolic localization (<xref ref-type="fig" rid="fig3">Fig. 3</xref>A).</p>
<p id="p0145">After co-localization analysis, we found that a significant NLRP3-ASC interaction was induced by LPS + ATP only in CTR fibroblasts (P &lt; 0.05); while, RTT cells showed a significant increase of inflammasome assembly already in basal condition (P &lt; 0.05; as compared to untreated CTR), and were unable to respond to further challenge with LPS + ATP (<xref ref-type="fig" rid="fig3">Fig. 3</xref>B).</p>
</sec>
<sec id="sec3.4">
<label>3.4</label>
<title>Altered levels of pro-CASP1 and active CASP1 form in RTT fibroblasts</title>
<p id="p0150">The key outcome of NLRP3-ASC assembly is the self-cleavage and activation of pro-CASP1 that, then, leads to the processing and maturation of the pro-inflammatory cytokines IL-1β and IL-18 [<xref ref-type="bibr" rid="bib12">12</xref>]. Given the higher levels of cleaved IL-1β and inflammasome assembly in RTT cells, we next evaluated the protein expression of the pro-form and active form of CASP1.</p>
<p id="p0155">In both basal and LPS + ATP stimulated conditions, RTT fibroblasts displayed low pro-CASP1 levels respect to the CTR cells (P &lt; 0.05) (<xref ref-type="fig" rid="fig4">Fig. 4</xref>A). The basal levels of CASP1 p20 active form were similar between CTR and RTT cells, while the treatment with LPS + ATP increased its levels in CTR cells (P &lt; 0.05), no change was observed in RTT fibroblasts after the pro-inflammatory stimulus (<xref ref-type="fig" rid="fig4">Fig. 4</xref>A).<fig id="fig4"><label>Fig. 4</label><caption><p>Altered protein and mRNA levels of caspase 1 in RTT fibroblasts.</p><p><bold>Panel A.</bold> Representative Western blots images for pro-CASP1 and active CASP1 p20 in control and RTT fibroblasts stimulated with LPS 100 μg/ml for 6 h and ATP 5 mM for 30 min. Quantification is showed in bottom panel. Data were given as means ± SD. CTR, control; RTT, Rett syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P &lt; 0.05. Results were analyzed by Two-way ANOVA, with post-hoc Tukey's multiple comparisons test. <bold>Panel B.</bold> The mRNA levels of pro-CASP1 were analyzed by real-time RT-PCR. Data are expressed as 2<sup>−ΔΔCt</sup>, using GAPDH as the reference, and one of the controls as the internal calibrator. Data are given as means ± SD. CTR, control; RTT, Rett syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P &lt; 0.05. Results were analyzed by Two-way ANOVA, with post-hoc Tukey's multiple comparisons test.</p></caption><alt-text id="alttext0045">Fig. 4</alt-text><graphic xlink:href="gr4"></graphic></fig></p>
<p id="p0160">To verify if regulation of pro-CASP1 protein expression occurs at the transcription level, we assessed its mRNA expression by real time PCR. As showed in <xref ref-type="fig" rid="fig4">Fig. 4</xref>B, in unstimulated conditions, RTT cells displayed a trend in reduction of pro-CASP1 mRNA levels compared to CTR fibroblasts. After LPS + ATP stimulation, pro-CASP1 gene expression showed a trend in increase in CTR cells, while no significant changes were observed in RTT fibroblasts (<xref ref-type="fig" rid="fig4">Fig. 4</xref>B).</p>
</sec>
<sec id="sec3.5">
<label>3.5</label>
<title>Increased release of inflammasome components in serum of RTT patients</title>
<p id="p0165">A growing body of evidence supports a model whereby the cellular release of inflammasome proteins through extracellular vesicles such as exosomes delivers their cargo <italic>in vivo</italic> to amplify the inflammatory signaling in peripheral tissues [<xref ref-type="bibr" rid="bib33">33</xref>,<xref ref-type="bibr" rid="bib34">34</xref>]. Therefore, to further study inflammasome activation in RTT, we evaluated the protein expression of the main inflammasome components in serum from RTT patients and control subjects. Consistent with the results obtained in fibroblasts, we found that ASC protein levels were higher in the serum of RTT patients than in the control group (<xref ref-type="fig" rid="fig5">Fig. 5</xref>A). Furthermore, immunoblot analysis of DSS-crosslinked ASC oligomers further confirmed a significant increase of catalytically active ASC oligomeric species in RTT serum samples (<xref ref-type="fig" rid="fig5">Fig. 5</xref>B). Next, as hallmark of inflammasome activation, we measured the serum levels of IL-18 by ELISA. As showed in <xref ref-type="fig" rid="fig5">Fig. 5</xref>C, serum IL-18 concentrations were significantly higher in RTT patients than in control subjects (p &lt; 0.05).<fig id="fig5"><label>Fig. 5</label><caption><p>Increased release of inflammasome components in serum of RTT patients.</p><p><bold>Panel A.</bold> Representative Western blots images for ASC in serum samples from control subjects and RTT patients. Quantification is showed in right panel. <bold>Panel B.</bold> Representative images and densitometric analysis of Western blotting for ASC oligomers in serum samples from control subjects and RTT patients. Quantification is showed in bottom panel. <bold>Panel C.</bold> Serum levels of IL-18 in control subjects and RTT patients were quantified by ELISA. For all the panels, the results are presented as means ± SD. CTR, control; RTT, Rett syndrome; *P &lt; 0.05. Results were analyzed by <italic>t</italic>-test for independent groups (CTR N = 17; RTT N = 41).</p></caption><alt-text id="alttext0050">Fig. 5</alt-text><graphic xlink:href="gr5"></graphic></fig></p>
</sec>
</sec>
<sec id="sec4">
<label>4</label>
<title>Discussion</title>
<p id="p0170">The aim of our work was to elucidate the possible involvement of the inflammasome pathway as a key player in RTT subclinical inflammation. Inflammasomes, cytoplasmic multi-protein complexes, provide host immune defense against a diverse range of pathogen infections and cellular stress signals [<xref ref-type="bibr" rid="bib11">11</xref>]. As previously mentioned, assembly of NLRP3/ASC inflammasome leads to subsequent recruitment and autocatalytic activation of CASP1 that, finally, promotes the maturation of IL-1β and IL-18 [<xref ref-type="bibr" rid="bib11">11</xref>,<xref ref-type="bibr" rid="bib35">35</xref>]. These key pro-inflammatory cytokines are able to promote a multitude of finely regulated immune responses useful for restoring the physiological conditions [<xref ref-type="bibr" rid="bib11">11</xref>]. However, it is also well known that an uncontrolled and prolonged inflammasome activation with an excessive release of cytokines can participate in the onset and progression of chronic inflammatory states associated with a wide variety of human diseases [<xref ref-type="bibr" rid="bib10">10</xref>,<xref ref-type="bibr" rid="bib36">36</xref>,<xref ref-type="bibr" rid="bib37">37</xref>].</p>
<p id="p0175">Although RTT is primarily a genetic brain disorder with prominent neurological symptoms, a vast body of evidence supports a key role for the interplay between redox imbalance and a subclinical inflammatory status (oxinflammation phenomenon) in different systemic abnormalities observed in RTT patients (<italic>i.e.,</italic> mitochondrial dysfunctions, metabolic alterations, immune dysregulation, gastrointestinal problems, breathing disturbances and recurrent infections) [<xref ref-type="bibr" rid="bib6">6</xref>,<xref ref-type="bibr" rid="bib38">38</xref>]. In this contest, the dysregulation of NLRP3 inflammasome pathway could be a new molecular mechanism able to contribute to RTT pathophysiology, in both brain and periphery.</p>
<p id="p0180">In general, although still under debate [<xref ref-type="bibr" rid="bib39">39</xref>], it is accepted that the molecular mechanisms leading to the inflammasome activation are mainly driven by two different signals. Typically, ‘signal 1’ or ‘priming’ molecules (<italic>e.g.</italic>, LPS) induce the expression of NLRP3, pro-IL-1β and pro-IL-18 <italic>via</italic> NF-κB activation [<xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib39">39</xref>]. Moreover, PAMPs or DAMPs (<italic>e.g.,</italic> ATP, particulate matter, heme, pathogen-associated RNA, etc) activate the NLRP3 inflammasome assembly (‘signal 2’) [<xref ref-type="bibr" rid="bib32">32</xref>]. The particular interest towards NLRP3 inflammasome lies in the broad range of molecular and cellular signaling events that are induced by its activators among which there are ionic flux (<italic>e.g.,</italic> K<sup>+</sup>, Na<sup>+</sup>, chloride fluxes and Ca<sup>2+</sup> signaling), ROS production, lysosomal destabilization, mitochondrial dysfunction and post-translational modifications of NLRP3 [<xref ref-type="bibr" rid="bib40">40</xref>,<xref ref-type="bibr" rid="bib41">41</xref>]. Of note, some of these stimuli are present in RTT patients [<xref ref-type="bibr" rid="bib42">42</xref>,<xref ref-type="bibr" rid="bib43">43</xref>] and, therefore, could promote a dysregulated NLRP3 inflammasome function that, in turn, could contribute to the typical RTT subclinical inflammation [<xref ref-type="bibr" rid="bib6">6</xref>,<xref ref-type="bibr" rid="bib38">38</xref>,<xref ref-type="bibr" rid="bib44">44</xref>].</p>
<p id="p0185">In the present work, RTT cells showed an increased steady level of nuclear NF-κB p65 subunit, as compared to CTR cells. A significant increase of NF-κB p65 nuclear translocation was found in CTR cells after LPS + ATP treatment, whereas RTT fibroblasts did not undergo any significant change in the transcription factor nuclear levels in response to the inflammatory <italic>stimuli</italic>. These peculiar results suggest that, in basal conditions, RTT fibroblasts exhibit a marked NF-κB p65 activation which amplitude cannot be achieved by control cells even upon pro-inflammatory stimulation. This indicates the occurrence of an already activated inflammatory response in RTT fibroblasts that, on the other hand, seem unable to respond to further pro-inflammatory challenges.</p>
<p id="p0190">Our results on the constitutively activated status of NF-κB p65 signaling with the subsequent increased levels of IL-1β; production of which is induced only in response to inflammatory <italic>stimuli</italic> [<xref ref-type="bibr" rid="bib45">45</xref>], may be likely related to the oxinflammation condition typical of RTT [<xref ref-type="bibr" rid="bib6">6</xref>,<xref ref-type="bibr" rid="bib38">38</xref>]. Indeed, multiple elements support the implication of a chronic, low-grade inflammation in RTT, including high levels of inflammatory markers and deregulation of acute phase response (APR) proteins, an unbalanced plasma cytokines profile coupled with an abnormal morphology of peripheral blood mononuclear cells (PBMCs) [<xref ref-type="bibr" rid="bib6">6</xref>]. Moreover, we recently demonstrated an increased gene expression of arachidonate 15-lipoxygenase (ALOX15) in RTT PBMC [<xref ref-type="bibr" rid="bib44">44</xref>]. This enzyme is able to oxidize polyunsaturated fatty acids such as linoleic acid, producing 13- and 9- hydroxyoctadecadienoic acid (13-HODE and 9-HODE, respectively); levels of these two compounds were found also increased in RTT serum [<xref ref-type="bibr" rid="bib44">44</xref>]. High HODEs levels are able to exert pro-inflammatory effects such as the induction of cytokines and cell adhesion molecules expression, the modulation of immune cells chemotaxis and monocyte adhesion to vascular endothelial cells and the activation of transcription factors including NF-κB [<xref ref-type="bibr" rid="bib46">46</xref>]. In addition, beyond the subclinical inflammation, also the redox imbalance, widely observed in RTT, could be another plausible mechanism able to induce the up-regulation of redox-sensitive transcriptional factors such as NF-κB [<xref ref-type="bibr" rid="bib47">47</xref>]. Of note, an aberrant NF-κB signaling has been already reported in RTT and related to MECP2 deficiency, in both patients and animal models. Alterations of the NF-kB pathway were first revealed in a transcriptional profiling study on the whole blood of RTT patients [<xref ref-type="bibr" rid="bib48">48</xref>]. Then, the possible involvement of MECP2 in immune function regulation was suggested by the enhanced NF-κB signaling coupled with an increased expression of inflammatory cytokines (<italic>i.e.,</italic> TNFα, IL-6, and IL-3) found in MECP2-deficient human PBMCs and in the human monocyte line THP1 [<xref ref-type="bibr" rid="bib49">49</xref>,<xref ref-type="bibr" rid="bib50">50</xref>]. In line with these works, microglia and macrophages from <italic>Mecp2</italic>-deficient mice displayed a deregulated inflammatory response with an abnormal transcriptional expression of inflammatory genes after TNFα stimulation [<xref ref-type="bibr" rid="bib51">51</xref>]. A study by Kishi and colleagues [<xref ref-type="bibr" rid="bib52">52</xref>] on the cortex of <italic>Mecp2</italic>-null mice demonstrated an abnormal upregulation of NF-κB signaling, which reduction ameliorated the dendritic complexity of callosal projection neurons and prolonged their normal lifespan. Similarly, a marked decrease in inflammation markers was observed in the cerebellar area of <italic>Mecp2</italic>-knockout mice after treatment with a specific glycogen synthase kinase-3b (Gsk3b) inhibitor that attenuated the nuclear NF-κB activity [<xref ref-type="bibr" rid="bib53">53</xref>]. Together, these evidence and our results suggest the hypothesis that NF-κB pathway dysregulation could play a significant role in RTT pathophysiology, as already proven in rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, atherosclerosis, systemic lupus erythematosus, type I diabetes, chronic obstructive pulmonary disease and asthma [<xref ref-type="bibr" rid="bib54">54</xref>].</p>
<p id="p0195">In addition to regulate multiple aspects of the immune and inflammatory functions, NF-κB also has a role in regulating the activation of inflammasomes by inducing the transcriptional expression of NLRP3, pro-IL-1β and pro-IL-18 [<xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib39">39</xref>]. Therefore, based on the evidence of a constitutive activation of NF-κB p65 in RTT fibroblasts, we continued our study by analyzing the main components of NLRP3 signaling pathway. In order to achieve an effective inflammasome-mediated response, the presence of the adaptor protein ASC is crucial, since it can recruit the pro-caspase-1 through a “caspase activation and recruitment domain” (CARD), facilitating caspase-1 dimerization and activation, thus ensuring the formation of a fully functional inflammasome [<xref ref-type="bibr" rid="bib55">55</xref>]. About ASC, as expected, LPS + ATP increased markedly the levels of ASC in CTR cells, whereas, although exhibiting significantly higher basal levels of ASC, as compared to CTR fibroblasts, RTT cells did not undergo any change upon LPS/ATP treatment. Several papers showed that ASC gene is under the control of a methylation-sensitive promoter [<xref ref-type="bibr" rid="bib56">56</xref>,<xref ref-type="bibr" rid="bib57">57</xref>]. In addition, Webb and colleagues [<xref ref-type="bibr" rid="bib58">58</xref>], by using an IRIDESCENT algorithm analysis, revealed that ASC is sensitive to MECP2 activity and, moreover, transcriptional silencing of ASC gene, associated with the complete methylation of its promoter region, was observed in prostate cancer [<xref ref-type="bibr" rid="bib59">59</xref>]. Therefore, we hypothesize that the loss of the transcriptional repression activity by a deficient MECP2 could be a mechanism able to explain the increase of ASC levels in RTT fibroblasts [<xref ref-type="bibr" rid="bib60">60</xref>]. Furthermore, the increased basal levels of ASC in RTT fibroblasts could also be another hypothetic molecular mechanism able to explain the constitutive NF-κB p65 hyperactivation. Indeed, there is evidence that identified ASC as an upstream regulator of NF-κB signaling [<xref ref-type="bibr" rid="bib61">61</xref>].</p>
<p id="p0200">Since NLRP3 protein expression in RTT fibroblasts was found to be substantially unchanged after LPS + ATP treatment, we performed a multiple immunofluorescence-based analysis of NLRP3 and ASC, in order to estimate the interaction between these proteins to determine the inflammasome assembly process [<xref ref-type="bibr" rid="bib20">20</xref>]. Our results provided evidence of an increased interaction between NLRP3 and ASC in unstimulated RTT cells. Furthermore, as expected, control fibroblasts showed increased NLRP3/ASC co-distribution, following the pro-inflammatory challenge, whereas RTT cells were unable to display a similar behavior. Such results are consistent with the data related to NF-κB p65 signaling and cytosolic ASC levels discussed above. The pre-activated status of NLRP3/ASC inflammasome could be also linked to the redox imbalance and the mitochondrial dysfunction, aspects repeatedly described in RTT [<xref ref-type="bibr" rid="bib42">42</xref>]. Indeed, mitochondrial events have been associated with NLRP3 activation in several different pathological conditions [<xref ref-type="bibr" rid="bib62">62</xref>]. By acting upstream of the NLRP3 activation, mitochondria can provide ROS to induce NLRP3 oligomerization and be a platform for inflammasome assembly [<xref ref-type="bibr" rid="bib63">63</xref>,<xref ref-type="bibr" rid="bib64">64</xref>]. Interestingly, recent findings also revealed a role for HODEs, that we found increased in RTT serum [<xref ref-type="bibr" rid="bib44">44</xref>], as positive modulators of NLRP3 inflammasome assembly and caspase-1 activation [<xref ref-type="bibr" rid="bib65">65</xref>].</p>
<p id="p0205">In addition, the LPS + ATP treatment enhanced the levels of the cleaved form of caspase-1 (p20) in CTR cells, in coherence with the increased co-localization of the sensor NLRP3 and the adaptor ASC proteins within the cytoplasm, thus confirming that the LPS + ATP promoted the functional assembly of inflammasome in fibroblasts from healthy individuals. In basal condition, RTT cells were found to have unchanged levels of CASP1 p20. However, the basal activation state of the CASP1 seemed to be higher in RTT fibroblasts than in CTR cells, as shown by the markedly lower pro-CASP1 protein levels found in fibroblasts from RTT patients. This idea was confirmed by the fact that RTT cells did not undergo any statistically significant change of CASP1 p20 protein level upon pro-inflammatory <italic>stimulus</italic>. In addition, since images on cleaved IL-1β showed an increased green signal in un-treated RTT fibroblasts, similar to the fluorescence intensity of LPS plus ATP stimulated CTR fibroblasts, we can suppose that CASP1 is able to properly work in the cleavage and maturation of IL-1β. While this finding requires further investigations, a plausible explanation for the levels of CASP1 (pro-form and mature form) observed in RTT could be found in an enhanced extracellular release trough extracellular vesicles like exosomes [<xref ref-type="bibr" rid="bib33">33</xref>,<xref ref-type="bibr" rid="bib34">34</xref>]. Indeed, in addition to NLRP3 and ASC specks [<xref ref-type="bibr" rid="bib66">66</xref>,<xref ref-type="bibr" rid="bib67">67</xref>], also caspase-1 is found in extracellular vesicles. Moreover, recent papers revealed that pro-caspase-1 could be also activated in extracellular compartments, leading to the subsequent cleavage of its substrates in exocytotic secretory pathways, such as exosomes, to disseminate the inflammatory signals to adjacent cells and tissues [<xref ref-type="bibr" rid="bib68">68</xref>].</p>
<p id="p0210">Based on the evidence of the extracellular release of inflammasome components and a recent report that showed increased concentrations of caspase-1, IL-1β and IL-18 in serum samples from ASD patients [<xref ref-type="bibr" rid="bib22">22</xref>] (clinically similar to RTT), we decided to confirm our <italic>in vitro</italic> results on RTT fibroblasts also in the serum from RTT patients. The increased serum levels of ASC oligomers and IL-18 corroborated our cellular findings on the occurrence of a deregulated inflammasome pathway in RTT. Indeed, there is evidence that ASC oligomers remain catalytically active in circulation and, after phagocytosis by adjacent cells, can propagate inflammasome activation, thereby augmenting the pro-inflammatory cascade [<xref ref-type="bibr" rid="bib67">67</xref>].</p>
<p id="p0215">Therefore, taken together our data suggest that de-regulated inflammasome activation may have a role in the occurrence of a subclinical inflammatory status in RTT. Several findings demonstrated that a low-grade inflammatory response, avoiding a negative feedback regulation, together with the presence of ROS during the inflammatory processes play a key role in several pathologies: genetic diseases [<xref ref-type="bibr" rid="bib11">11</xref>,<xref ref-type="bibr" rid="bib69">69</xref>], diabetes [<xref ref-type="bibr" rid="bib70">70</xref>], cardiovascular disease [<xref ref-type="bibr" rid="bib71">71</xref>], cancer [<xref ref-type="bibr" rid="bib72">72</xref>], and neurodegenerative disorders, such as Alzheimer's and Parkinson's disease [<xref ref-type="bibr" rid="bib73">73</xref>]. Some of these pathologies have been associated to inflammasome de-regulated activation [<xref ref-type="bibr" rid="bib21">21</xref>,<xref ref-type="bibr" rid="bib32">32</xref>].</p>
<p id="p0220">In addition, several authors demonstrated that ROS production, via the NAD(P)H-oxidase (NOX) activity, induces the formation and activation of NLRP3 inflammasome in different <italic>in vitro</italic> and <italic>in vivo</italic> models [<xref ref-type="bibr" rid="bib74">74</xref>,<xref ref-type="bibr" rid="bib75">75</xref>]. Cervellati and co-workers [<xref ref-type="bibr" rid="bib7">7</xref>] demonstrated that RTT fibroblasts exhibited high NOX enzymatic activity, together with increased levels of superoxide anion and hydrogen peroxide. Hence, the reported inflammasome activation in RTT may be likely due also to a NOX-dependent response.</p>
<p id="p0225">Our experiments show that RTT fibroblasts were unable to activate an inflammasome-dependent response to pro-inflammatory <italic>stimuli</italic>, since they exhibited an already altered machinery, thus suggesting a role of inflammasome in the subclinical inflammatory status, characterizing the pathology (<xref ref-type="fig" rid="sch1">Scheme 1</xref>) [<xref ref-type="bibr" rid="bib6">6</xref>,<xref ref-type="bibr" rid="bib38">38</xref>]. It is known that stimulation of the immune system in response to sterile insults can lead to chronic debilitating conditions. Hence, for insulted cells it is crucial to coordinate the recognition, initiation, and elaboration of signals inducing inflammasome response, in order to promote the resolution. Whereas a dysregulation of this system can result in disease [<xref ref-type="bibr" rid="bib14">14</xref>].<fig id="sch1"><label>Scheme 1</label><caption><p>Proposed mechanisms of inflammasome involvement in RTT OxInflammation.</p><p>The scheme summarizes the basal and LPS + ATP-stimulated status of the inflammasome pathway by comparing the responses of CTR and RTT fibroblasts. As showed in the right panels, RTT fibroblasts were unable to further activate an inflammasome-dependent response to the pro-inflammatory stimulus with LPS and ATP (bottom panel). Indeed, already in basal conditions (upper panel), they exhibited a pre-activated state of the inflammasome machinery, consisting in increased NLRP3/ASC interaction, CASP1 activation and cleaved IL-1β expression, coupled with an enhanced nuclear translocation of NF-κB p65 subunit. In addition, the deregulation of inflammasome pathway was associated with increased levels of inflammasome components in patient-derived serum. In conclusion, a state of constitutive inflammasome activation could play a key role in RTT oxinflammation by fueling and perpetuating the subclinical inflammatory condition observed in this syndrome.</p></caption><alt-text id="alttext0055">Scheme 1</alt-text><graphic xlink:href="sc1"></graphic></fig></p>
</sec>
<sec id="sec5">
<label>5</label>
<title>Conclusions</title>
<p id="p0230">In conclusion, we report that, along with oxidative stress and mitochondrial dysfunction, a state of constitutive activation of the inflammasome system occurs in RTT, which, in turn, may feed and perpetuate the subclinical inflammatory condition observed in this disease.</p>
</sec>
<sec sec-type="COI-statement">
<title>Declaration of competing interest</title>
<p id="p0235">The authors declare no conflict of interests.</p>
</sec>
</body>
<back>
<ref-list id="cebib0010">
<title>References</title>
<ref id="bib1">
<label>1</label>
<element-citation id="sref1" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Rett</surname>
<given-names>A.</given-names>
</name>
</person-group>
<chapter-title>Über ein zerebral-atrophisches Syndrom bei Hyperammonämie</chapter-title>
<year>1966</year>
<publisher-name>Hollinek</publisher-name>
<publisher-loc>Wien</publisher-loc>
</element-citation>
</ref>
<ref id="bib2">
<label>2</label>
<element-citation id="sref2" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bienvenu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Philippe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Roux</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Raynaud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bonnefond</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lesca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jonveaux</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moncla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feingold</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chelly</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Villard</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The incidence of Rett syndrome in France</article-title>
<source/>Pediatr. Neurol.
          <volume>34</volume>
<year>2006</year>
<fpage>372</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="pmid">16647997</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<label>3</label>
<element-citation id="sref3" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amir</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Van den Veyver</surname>
<given-names>I.B.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>C.Q.</given-names>
</name>
<name>
<surname>Francke</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title>
<source/>Nat. Genet.
          <volume>23</volume>
<year>1999</year>
<fpage>185</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">10508514</pub-id>
</element-citation>
</ref>
<ref id="bib4">
<label>4</label>
<element-citation id="sref4" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neul</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Glaze</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Bahi-Buisson</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>M.E.S.</given-names>
</name>
<name>
<surname>Schanen</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Zappella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Renieri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huppke</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Percy</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Consortium</surname>
<given-names>RettSearch</given-names>
</name>
</person-group>
<article-title>Rett syndrome: revised diagnostic criteria and nomenclature</article-title>
<source/>Ann. Neurol.
          <volume>68</volume>
<year>2010</year>
<fpage>944</fpage>
<lpage>950</lpage>
<pub-id pub-id-type="pmid">21154482</pub-id>
</element-citation>
</ref>
<ref id="bib5">
<label>5</label>
<element-citation id="sref5" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Einspieler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Freilinger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marschik</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Behavioural biomarkers of typical Rett syndrome: moving towards early identification</article-title>
<source/>Wien. Med. Wochenschr.
          <volume>166</volume>
<year>2016</year>
<fpage>333</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">27514944</pub-id>
</element-citation>
</ref>
<ref id="bib6">
<label>6</label>
<element-citation id="sref6" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>OxInflammation in Rett syndrome</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <volume>81</volume>
<year>2016</year>
<fpage>246</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="pmid">27425398</pub-id>
</element-citation>
</ref>
<ref id="bib7">
<label>7</label>
<element-citation id="sref7" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Romani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>De Rasmo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Signorile</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Milanese</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mastroberardino</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Savelli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Impaired enzymatic defensive activity, mitochondrial dysfunction and proteasome activation are involved in RTT cell oxidative damage</article-title>
<source/>Biochim. Biophys. Acta
          <volume>1852</volume>
<year>2015</year>
<fpage>2066</fpage>
<lpage>2074</lpage>
<pub-id pub-id-type="pmid">26189585</pub-id>
</element-citation>
</ref>
<ref id="bib8">
<label>8</label>
<element-citation id="sref8" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giardini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D'Esposito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Filosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Increased levels of 4HNE-protein plasma adducts in Rett syndrome</article-title>
<source/>Clin. Biochem.
          <volume>44</volume>
<year>2011</year>
<fpage>368</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">21276437</pub-id>
</element-citation>
</ref>
<ref id="bib9">
<label>9</label>
<element-citation id="sref9" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Virgili</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>OxInflammation: from subclinical condition to pathological biomarker</article-title>
<source/>Front. Physiol.
          <volume>9</volume>
<year>2018</year>
<fpage>858</fpage>
<pub-id pub-id-type="pmid">30038581</pub-id>
</element-citation>
</ref>
<ref id="bib10">
<label>10</label>
<element-citation id="sref10" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abderrazak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Syrovets</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Couchie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>El Hadri</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Friguet</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Simmet</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rouis</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases</article-title>
<source/>Redox Biol
          <volume>4</volume>
<year>2015</year>
<fpage>296</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">25625584</pub-id>
</element-citation>
</ref>
<ref id="bib11">
<label>11</label>
<element-citation id="sref11" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dixit</surname>
<given-names>V.M.</given-names>
</name>
</person-group>
<article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title>
<source/>Nat. Rev. Immunol.
          <volume>16</volume>
<year>2016</year>
<fpage>407</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="pmid">27291964</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<label>12</label>
<element-citation id="sref12" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathinam</surname>
<given-names>V.A.K.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Inflammasome complexes: emerging mechanisms and effector functions</article-title>
<source/>Cell
          <volume>165</volume>
<year>2016</year>
<fpage>792</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="pmid">27153493</pub-id>
</element-citation>
</ref>
<ref id="bib13">
<label>13</label>
<element-citation id="sref13" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evavold</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kagan</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages</article-title>
<source/>Immunity
          <volume>48</volume>
<year>2018</year>
<fpage>35</fpage>
<lpage>44</lpage>
<comment>e6</comment>
<pub-id pub-id-type="pmid">29195811</pub-id>
</element-citation>
</ref>
<ref id="bib14">
<label>14</label>
<element-citation id="sref14" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>J.P.Y.</given-names>
</name>
</person-group>
<article-title>The inflammasome NLRs in immunity, inflammation, and associated diseases</article-title>
<source/>Annu. Rev. Immunol.
          <volume>29</volume>
<year>2011</year>
<fpage>707</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="pmid">21219188</pub-id>
</element-citation>
</ref>
<ref id="bib15">
<label>15</label>
<element-citation id="sref15" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>The contrasting roles of inflammasomes in cancer</article-title>
<source/>Am J Cancer Res
          <volume>8</volume>
<year>2018</year>
<fpage>566</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="pmid">29736304</pub-id>
</element-citation>
</ref>
<ref id="bib16">
<label>16</label>
<element-citation id="sref16" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moossavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parsamanesh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bahrami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Sahebkar</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Role of the NLRP3 inflammasome in cancer</article-title>
<source/>Mol. Cancer
          <volume>17</volume>
<year>2018</year>
<fpage>158</fpage>
<pub-id pub-id-type="pmid">30447690</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<label>17</label>
<element-citation id="sref17" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Kanneganti</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>Inflammasomes and autoimmunity</article-title>
<source/>Trends Mol. Med.
          <volume>17</volume>
<year>2011</year>
<fpage>57</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">21163704</pub-id>
</element-citation>
</ref>
<ref id="bib18">
<label>18</label>
<element-citation id="sref18" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>Y.S.</given-names>
</name>
</person-group>
<article-title>Role of inflammasomes in inflammatory autoimmune rheumatic diseases</article-title>
<source/>KOREAN J. PHYSIOL. PHARMACOL.
          <volume>22</volume>
<year>2018</year>
<fpage>1</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">29302207</pub-id>
</element-citation>
</ref>
<ref id="bib19">
<label>19</label>
<element-citation id="sref19" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tardivel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thorens</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Thioredoxin-interacting protein links oxidative stress to inflammasome activation</article-title>
<source/>Nat. Immunol.
          <volume>11</volume>
<year>2010</year>
<fpage>136</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">20023662</pub-id>
</element-citation>
</ref>
<ref id="bib20">
<label>20</label>
<element-citation id="sref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saresella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>La Rosa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Piancone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zoppis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marventano</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rainone</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nemni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mancuso</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clerici</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease</article-title>
<source/>Mol. Neurodegener.
          <volume>11</volume>
<year>2016</year>
<fpage>23</fpage>
<pub-id pub-id-type="pmid">26939933</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<label>21</label>
<element-citation id="sref21" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>NLRP3 inflammasome in neurological diseases, from functions to therapies</article-title>
<source/>Front. Cell. Neurosci.
          <volume>11</volume>
<year>2017</year>
<fpage>63</fpage>
<pub-id pub-id-type="pmid">28337127</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<label>22</label>
<element-citation id="sref22" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saresella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piancone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marventano</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zoppis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hernis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zanette</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trabattoni</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chiappedi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Canevini</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>la Rosa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clerici</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Multiple inflammasome complexes are activated in autistic spectrum disorders</article-title>
<source/>Brain Behav. Immun.
          <volume>57</volume>
<year>2016</year>
<fpage>125</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">26979869</pub-id>
</element-citation>
</ref>
<ref id="bib23">
<label>23</label>
<element-citation id="sref23" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Scavenger receptor B1 post-translational modifications in Rett syndrome</article-title>
<source/>FEBS Lett.
          <volume>587</volume>
<year>2013</year>
<fpage>2199</fpage>
<lpage>2204</lpage>
<pub-id pub-id-type="pmid">23711372</pub-id>
</element-citation>
</ref>
<ref id="bib24">
<label>24</label>
<element-citation id="sref24" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Dexmedetomidine inhibits inflammation in microglia cells under stimulation of LPS and ATP by c-Fos/NLRP3/caspase-1 cascades</article-title>
<source/>EXCLI J
          <volume>17</volume>
<year>2018</year>
<fpage>302</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="pmid">29743866</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<label>25</label>
<element-citation id="sref25" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Mechanisms that lead to the regulation of NLRP3 inflammasome expression and activation in human dental pulp fibroblasts</article-title>
<source/>Mol. Immunol.
          <volume>66</volume>
<year>2015</year>
<fpage>253</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="pmid">25863775</pub-id>
</element-citation>
</ref>
<ref id="bib26">
<label>26</label>
<element-citation id="sref26" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cortelazzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mirasole</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guerranti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trentini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zolla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Savelli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Proteomic analysis of 4-hydroxynonenal and nitrotyrosine modified proteins in RTT fibroblasts</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <volume>81</volume>
<year>2016</year>
<fpage>236</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">27495376</pub-id>
</element-citation>
</ref>
<ref id="bib27">
<label>27</label>
<element-citation id="sref27" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Meloni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gardi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cortelazzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Renieri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jay Forman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder</article-title>
<source/>Free Radic. Biol. Med.
          <volume>86</volume>
<year>2015</year>
<fpage>156</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="pmid">26006105</pub-id>
</element-citation>
</ref>
<ref id="bib28">
<label>28</label>
<element-citation id="sref28" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordone</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benedusi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Falone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Amicarelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Antiglycative activity and RAGE expression in Rett syndrome</article-title>
<source/>Cells
          <volume>8</volume>
<year>2019</year>
</element-citation>
</ref>
<ref id="bib29">
<label>29</label>
<element-citation id="sref29" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>
<source/>Methods
          <volume>25</volume>
<year>2001</year>
<fpage>402</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="pmid">11846609</pub-id>
</element-citation>
</ref>
<ref id="bib30">
<label>30</label>
<element-citation id="sref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moser</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hochreiter</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Herbst</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Fluorescence colocalization microscopy analysis can be improved by combining object-recognition with pixel-intensity-correlation</article-title>
<source/>Biotechnol. J.
          <volume>12</volume>
<year>2017</year>
</element-citation>
</ref>
<ref id="bib31">
<label>31</label>
<element-citation id="sref31" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crivellari</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Lactonase activity and lipoprotein-phospholipase A(2) as possible novel serum biomarkers for the differential diagnosis of autism spectrum disorders and Rett syndrome: results from a pilot study</article-title>
<source/>Oxid Med Cell Longev
          <volume>2017</volume>
<year>2017</year>
<object-id pub-id-type="publisher-id">5694058</object-id>
</element-citation>
</ref>
<ref id="bib32">
<label>32</label>
<element-citation id="sref32" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>J.P.Y.</given-names>
</name>
</person-group>
<article-title>Inflammasomes: mechanism of action, role in disease, and therapeutics</article-title>
<source/>Nat. Med.
          <volume>21</volume>
<year>2015</year>
<fpage>677</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="pmid">26121197</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<label>33</label>
<element-citation id="sref33" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albornoz</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Woodruff</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Inflammasomes in CNS diseases</article-title>
<source/>Exp. Suppl.
          <volume>108</volume>
<year>2018</year>
<fpage>41</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">30536167</pub-id>
</element-citation>
</ref>
<ref id="bib34">
<label>34</label>
<element-citation id="sref34" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>García-Contreras</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abbassi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mejias</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Desousa</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Ricordi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Keane</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>de Rivero Vaccari</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Inflammasome proteins in serum and serum-derived extracellular vesicles as biomarkers of stroke</article-title>
<source/>Front. Mol. Neurosci.
          <volume>11</volume>
<year>2018</year>
<fpage>309</fpage>
<pub-id pub-id-type="pmid">30233311</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<label>35</label>
<element-citation id="sref35" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteleone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Bezbradica</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>von Pein</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Holley</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Boucher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shakespear</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Kapetanovic</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rolfes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Stow</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Interleukin-1ß maturation triggers its relocation to the plasma membrane for gasdermin-D-dependent and -independent secretion</article-title>
<source/>Cell Rep.
          <volume>24</volume>
<year>2018</year>
<fpage>1425</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="pmid">30089254</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<label>36</label>
<element-citation id="sref36" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Duewell</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>NLRP3 inflammasome activation in inflammaging</article-title>
<source/>Semin. Immunol.
          <volume>40</volume>
<year>2018</year>
<fpage>61</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">30268598</pub-id>
</element-citation>
</ref>
<ref id="bib37">
<label>37</label>
<element-citation id="sref37" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutterwala</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Haasken</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cassel</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>Mechanism of NLRP3 inflammasome activation</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <volume>1319</volume>
<year>2014</year>
<fpage>82</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">24840700</pub-id>
</element-citation>
</ref>
<ref id="bib38">
<label>38</label>
<element-citation id="sref38" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>4-hydroxynonenal protein adducts: key mediator in Rett syndrome oxinflammation</article-title>
<source/>Free Radic. Biol. Med.
          <volume>111</volume>
<year>2017</year>
<fpage>270</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="pmid">28063942</pub-id>
</element-citation>
</ref>
<ref id="bib39">
<label>39</label>
<element-citation id="sref39" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Place</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Kanneganti</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>Recent advances in inflammasome biology</article-title>
<source/>Curr. Opin. Immunol.
          <volume>50</volume>
<year>2018</year>
<fpage>32</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">29128729</pub-id>
</element-citation>
</ref>
<ref id="bib40">
<label>40</label>
<element-citation id="sref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelley</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jeltema</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The NLRP3 inflammasome: an overview of mechanisms of activation and regulation</article-title>
<source/>Int. J. Mol. Sci.
          <volume>20</volume>
<year>2019</year>
</element-citation>
</ref>
<ref id="bib41">
<label>41</label>
<element-citation id="sref41" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kouadir</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors</article-title>
<source/>Cell Death Dis.
          <volume>10</volume>
<year>2019</year>
<comment>128</comment>
</element-citation>
</ref>
<ref id="bib42">
<label>42</label>
<element-citation id="sref42" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D'Esposito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hajek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome</article-title>
<source/>Free Radic. Biol. Med.
          <volume>88</volume>
<year>2015</year>
<fpage>81</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">25960047</pub-id>
</element-citation>
</ref>
<ref id="bib43">
<label>43</label>
<element-citation id="sref43" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Disturbed redox homeostasis and oxidative stress: potential players in the developmental regression in Rett syndrome</article-title>
<source/>Neurosci. Biobehav. Rev.
          <volume>98</volume>
<year>2019</year>
<fpage>154</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">30639673</pub-id>
</element-citation>
</ref>
<ref id="bib44">
<label>44</label>
<element-citation id="sref44" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cordone</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Amicarelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>13-HODE, 9-HODE and ALOX15 as potential players in Rett syndrome oxInflammation</article-title>
<source/>Free Radic. Biol. Med.
          <volume>134</volume>
<year>2019</year>
<fpage>598</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="pmid">30743046</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<label>45</label>
<element-citation id="sref45" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Kanneganti</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>Cutting edge: distinct regulatory mechanisms control proinflammatory cytokines IL-18 and IL-1β</article-title>
<source/>J. Immunol.
          <volume>198</volume>
<year>2017</year>
<fpage>4210</fpage>
<lpage>4215</lpage>
<pub-id pub-id-type="pmid">28468974</pub-id>
</element-citation>
</ref>
<ref id="bib46">
<label>46</label>
<element-citation id="sref46" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rolin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Maghazachi</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Implications of chemokines, chemokine receptors, and inflammatory lipids in atherosclerosis</article-title>
<source/>J. Leukoc. Biol.
          <volume>95</volume>
<year>2014</year>
<fpage>575</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="pmid">24493826</pub-id>
</element-citation>
</ref>
<ref id="bib47">
<label>47</label>
<element-citation id="sref47" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hirao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus</article-title>
<source/>Antioxidants Redox Signal.
          <volume>7</volume>
<year>2005</year>
<fpage>395</fpage>
<lpage>403</lpage>
</element-citation>
</ref>
<ref id="bib48">
<label>48</label>
<element-citation id="sref48" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colak</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Al-Dhalaan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nester</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Albakheet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al-Younes</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Al-Hassnan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Al-Dosari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chedrawi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al-Owain</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abudheim</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Al-Alwan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Al-Odaib</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozand</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Inan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Genomic and transcriptomic analyses distinguish classic Rett and Rett-like syndrome and reveals shared altered pathways</article-title>
<source/>Genomics
          <volume>97</volume>
<year>2011</year>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">20934504</pub-id>
</element-citation>
</ref>
<ref id="bib49">
<label>49</label>
<element-citation id="sref49" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Driscoll</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Bressler</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Relationship between Mecp2 and NFκb signaling during neural differentiation of P19 cells</article-title>
<source/>Brain Res.
          <volume>1490</volume>
<year>2013</year>
<fpage>35</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">23123205</pub-id>
</element-citation>
</ref>
<ref id="bib50">
<label>50</label>
<element-citation id="sref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Driscoll</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Bressler</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells</article-title>
<source/>J. Neuroimmunol.
          <volume>283</volume>
<year>2015</year>
<fpage>23</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">26004152</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<label>51</label>
<element-citation id="sref51" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cronk</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Derecki</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lampano</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Smirnov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Norris</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Coddington</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Aderem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klibanov</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Litvak</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kipnis</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli</article-title>
<source/>Immunity
          <volume>42</volume>
<year>2015</year>
<fpage>679</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="pmid">25902482</pub-id>
</element-citation>
</ref>
<ref id="bib52">
<label>52</label>
<element-citation id="sref52" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Molyneaux</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Azim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Macklis</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice</article-title>
<source/>Nat. Commun.
          <volume>7</volume>
<year>2016</year>
<fpage>10520</fpage>
<pub-id pub-id-type="pmid">26821816</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<label>53</label>
<element-citation id="sref53" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jorge-Torres</surname>
<given-names>O.C.</given-names>
</name>
<name>
<surname>Szczesna</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Roa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Casal</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gonzalez-Somermeyer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Martínez-San Segundo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Petazzi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sáez</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Delgado-Morales</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fourcade</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pujol</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huertas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Llobet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Guil</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Esteller</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inhibition of Gsk3b reduces Nfkb1 signaling and rescues synaptic activity to improve the Rett syndrome phenotype in Mecp2-knockout mice</article-title>
<source/>Cell Rep.
          <volume>23</volume>
<year>2018</year>
<fpage>1665</fpage>
<lpage>1677</lpage>
<pub-id pub-id-type="pmid">29742424</pub-id>
</element-citation>
</ref>
<ref id="bib54">
<label>54</label>
<element-citation id="sref54" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity</article-title>
<source/>J. Autoimmun.
          <volume>31</volume>
<year>2008</year>
<fpage>245</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">18539434</pub-id>
</element-citation>
</ref>
<ref id="bib55">
<label>55</label>
<element-citation id="sref55" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boucher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Monteleone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coll</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Holley</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Bierschenk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stacey</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Yap</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Bezbradica</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity</article-title>
<source/>J. Exp. Med.
          <volume>215</volume>
<year>2018</year>
<fpage>827</fpage>
<lpage>840</lpage>
<pub-id pub-id-type="pmid">29432122</pub-id>
</element-citation>
</ref>
<ref id="bib56">
<label>56</label>
<element-citation id="sref56" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butts</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dunbar</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Corwin</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Gary</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>ASC Methylation and interleukin-1β are associated with aerobic capacity in heart failure</article-title>
<source/>Med. Sci. Sport. Exerc.
          <volume>49</volume>
<year>2017</year>
<fpage>1072</fpage>
<lpage>1078</lpage>
</element-citation>
</ref>
<ref id="bib57">
<label>57</label>
<element-citation id="sref57" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collard</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Harya</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Monzon</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>O'Keefe</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Methylation of the ASC gene promoter is associated with aggressive prostate cancer</article-title>
<source/>The Prostate
          <volume>66</volume>
<year>2006</year>
<fpage>687</fpage>
<lpage>695</lpage>
<pub-id pub-id-type="pmid">16425203</pub-id>
</element-citation>
</ref>
<ref id="bib58">
<label>58</label>
<element-citation id="sref58" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wren</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Jeffries</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kimberly</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Edberg</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ramsey-Goldman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Petri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reveille</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Alarcón</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Vilá</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Alarcón-Riquelme</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Vyse</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Gaffney</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Gilkeson</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Harley</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Sawalha</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus</article-title>
<source/>Arthritis Rheum.
          <volume>60</volume>
<year>2009</year>
<fpage>1076</fpage>
<lpage>1084</lpage>
<pub-id pub-id-type="pmid">19333917</pub-id>
</element-citation>
</ref>
<ref id="bib59">
<label>59</label>
<element-citation id="sref59" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vanwert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ferdinand</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gopisetty</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Singal</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Methylation mediated silencing of TMS1/ASC gene in prostate cancer</article-title>
<source/>Mol. Cancer
          <volume>5</volume>
<year>2006</year>
<fpage>28</fpage>
<pub-id pub-id-type="pmid">16848908</pub-id>
</element-citation>
</ref>
<ref id="bib60">
<label>60</label>
<element-citation id="sref60" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinde</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gabel</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Reading the unique DNA methylation landscape of the brain: non-CpG methylation, hydroxymethylation, and MeCP2</article-title>
<source/>Proc. Natl. Acad. Sci. U.S.A.
          <volume>112</volume>
<year>2015</year>
<fpage>6800</fpage>
<lpage>6806</lpage>
<pub-id pub-id-type="pmid">25739960</pub-id>
</element-citation>
</ref>
<ref id="bib61">
<label>61</label>
<element-citation id="sref61" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manji</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Geddes</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Merriam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Al-Garawi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lora</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Briskin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jurman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>DiStefano</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Bertin</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B</article-title>
<source/>J. Biol. Chem.
          <volume>277</volume>
<year>2002</year>
<fpage>11570</fpage>
<lpage>11575</lpage>
<pub-id pub-id-type="pmid">11786556</pub-id>
</element-citation>
</ref>
<ref id="bib62">
<label>62</label>
<element-citation id="sref62" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yabal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calleja</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Lawlor</surname>
<given-names>K.E.</given-names>
</name>
</person-group>
<article-title>Stressing out the mitochondria: mechanistic insights into NLRP3 inflammasome activation</article-title>
<source/>J. Leukoc. Biol.
          <volume>105</volume>
<year>2019</year>
<fpage>377</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="pmid">30589456</pub-id>
</element-citation>
</ref>
<ref id="bib63">
<label>63</label>
<element-citation id="sref63" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname>
<given-names>E.I.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Banoth</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Stotland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Sutterwala</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Cassel</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>Cutting edge: mitochondrial assembly of the NLRP3 inflammasome complex is initiated at priming</article-title>
<source/>J. Immunol.
          <volume>200</volume>
<year>2018</year>
<fpage>3047</fpage>
<lpage>3052</lpage>
<pub-id pub-id-type="pmid">29602772</pub-id>
</element-citation>
</ref>
<ref id="bib64">
<label>64</label>
<element-citation id="sref64" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yazdi</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Menu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title>
<source/>Nature
          <volume>469</volume>
<year>2011</year>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">21124315</pub-id>
</element-citation>
</ref>
<ref id="bib65">
<label>65</label>
<element-citation id="sref65" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuster</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Hennebelle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holtmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Taha</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Kirpich</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Eguchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramsden</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Papouchado</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Feldstein</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice</article-title>
<source/>J. Lipid Res.
          <volume>59</volume>
<year>2018</year>
<fpage>1597</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="pmid">30084831</pub-id>
</element-citation>
</ref>
<ref id="bib66">
<label>66</label>
<element-citation id="sref66" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cypryk</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nyman</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Matikainen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>From inflammasome to exosome-does extracellular vesicle secretion constitute an inflammasome-dependent immune response?</article-title>
<source/>Front. Immunol.
          <volume>9</volume>
<year>2018</year>
<fpage>2188</fpage>
<pub-id pub-id-type="pmid">30319640</pub-id>
</element-citation>
</ref>
<ref id="bib67">
<label>67</label>
<element-citation id="sref67" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franklin</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Bossaller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Nardo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ratter</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Stutz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Engels</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Brenker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nordhoff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mirandola</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Al-Amoudi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mangan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Monks</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Fricke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Espevik</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jarnicki</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Hansbro</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Busto</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marshak-Rothstein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hornemann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aguzzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kastenmüller</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Latz</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The adaptor ASC has extracellular and “prionoid” activities that propagate inflammation</article-title>
<source/>Nat. Immunol.
          <volume>15</volume>
<year>2014</year>
<fpage>727</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="pmid">24952505</pub-id>
</element-citation>
</ref>
<ref id="bib68">
<label>68</label>
<element-citation id="sref68" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nanayakkara</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lavallee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Novel extracellular and nuclear caspase-1 and inflammasomes propagate inflammation and regulate gene expression: a comprehensive database mining study</article-title>
<source/>J. Hematol. Oncol.
          <volume>9</volume>
<year>2016</year>
<fpage>122</fpage>
<pub-id pub-id-type="pmid">27842563</pub-id>
</element-citation>
</ref>
<ref id="bib69">
<label>69</label>
<element-citation id="sref69" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perluigi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia</article-title>
<source/>Curr Gerontol Geriatr Res
          <volume>2012</volume>
<year>2012</year>
<fpage>724904</fpage>
<pub-id pub-id-type="pmid">22203843</pub-id>
</element-citation>
</ref>
<ref id="bib70">
<label>70</label>
<element-citation id="sref70" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaneto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Katakami</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kawamori</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Miyatsuka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Matsuhisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Involvement of oxidative stress in the pathogenesis of diabetes</article-title>
<source/>Antioxidants Redox Signal.
          <volume>9</volume>
<year>2007</year>
<fpage>355</fpage>
<lpage>366</lpage>
</element-citation>
</ref>
<ref id="bib71">
<label>71</label>
<element-citation id="sref71" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenzel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kossmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Münzel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Daiber</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Redox regulation of cardiovascular inflammation - immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species</article-title>
<source/>Free Radic. Biol. Med.
          <volume>109</volume>
<year>2017</year>
<fpage>48</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">28108279</pub-id>
</element-citation>
</ref>
<ref id="bib72">
<label>72</label>
<element-citation id="sref72" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Fredrikson</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Ericson</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Gullberg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hedblad</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Engström</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Borgquist</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wirfält</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Low-grade inflammation, oxidative stress and risk of invasive post-menopausal breast cancer - a nested case-control study from the malmö diet and cancer cohort</article-title>
<source/>PLoS One
          <volume>11</volume>
<year>2016</year>
<object-id pub-id-type="publisher-id">e0158959</object-id>
</element-citation>
</ref>
<ref id="bib73">
<label>73</label>
<element-citation id="sref73" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heneka</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>El Khoury</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Brosseron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Wyss-Coray</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vitorica</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ransohoff</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Herrup</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Frautschy</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Finsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Verkhratsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koistinaho</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Latz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Halle</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Petzold</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Town</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shinohara</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>V.H.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bazan</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Hunot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Deigendesch</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Garaschuk</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Boddeke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dinarello</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Breitner</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Golenbock</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Kummer</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in Alzheimer's disease</article-title>
<source/>Lancet Neurol.
          <volume>14</volume>
<year>2015</year>
<fpage>388</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">25792098</pub-id>
</element-citation>
</ref>
<ref id="bib74">
<label>74</label>
<element-citation id="sref74" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dhandapani</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Brann</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>NADPH oxidase 2 regulates NLRP3 inflammasome activation in the brain after traumatic brain injury</article-title>
<source/>Oxid Med Cell Longev
          <volume>2017</volume>
<year>2017</year>
<comment>6057609</comment>
</element-citation>
</ref>
<ref id="bib75">
<label>75</label>
<element-citation id="sref75" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>How the phagocyte NADPH oxidase regulates innate immunity</article-title>
<source/>Free Radic. Biol. Med.
          <volume>125</volume>
<year>2018</year>
<fpage>44</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">29953922</pub-id>
</element-citation>
</ref>
</ref-list>
<sec id="appsec1" sec-type="supplementary-material">
<label>Appendix A</label>
<title>Supplementary data</title>
<p id="p0240">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.ppt"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Multimedia component 2</title></caption><media xlink:href="mmc2.xml"><alt-text>Multimedia component 2</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><title>Multimedia component 3</title></caption><media xlink:href="mmc3.docx"><alt-text>Multimedia component 3</alt-text></media></supplementary-material></p>
</sec>
<fn-group>
<fn fn-type="supplementary-material" id="appsec2">
<label>Appendix A</label>
<p id="p0245">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://doi.org/10.1016/j.redox.2019.101334">https://doi.org/10.1016/j.redox.2019.101334</ext-link>.</p>
</fn>
</fn-group>
</back>
</article>
</pmc-articleset>